Search
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin help...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesColtuximab ravtansine
go.drugbank.com/drugs/DB06342InvestigationalColtuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsArmodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalEtravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAvasimibe
go.drugbank.com/drugs/DB06442ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InducersDotarizine
go.drugbank.com/drugs/DB06446ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRemacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPropentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigationalPrucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further develo...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesMuraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates